2003
DOI: 10.1093/brain/awg175
|View full text |Cite
|
Sign up to set email alerts
|

Focal thinning of the cerebral cortex in multiple sclerosis

Abstract: Brain atrophy as determined by quantitative MRI can be used to characterize disease progression in multiple sclerosis. Many studies have addressed white matter (WM) alterations leading to atrophy, while changes of the cerebral cortex have been studied to a lesser extent. In vivo, the cerebral cortex has been difficult to study due to its complex structure and regional variability. Measurement of cerebral cortex thickness at different disease stages may provide new insights into grey matter (GM) pathology. In t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

41
278
4
3

Year Published

2005
2005
2012
2012

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 362 publications
(326 citation statements)
references
References 47 publications
41
278
4
3
Order By: Relevance
“…However, this is unlikely since the correlation between cortical thickness and age, in our patient sample, revealed statistically significant areas bilaterally in premotor and primary sensorimotor and visual cortices, confirming previous findings in normal aging (Salat et al, 2004). The low degree of cortical thinning per either TWMLL or disability score in primary sensorimotor areas in our relatively mildly impaired patients suggests that atrophy of primary motor cortex preferentially appears later in the disease course (Sailer et al, 2003).…”
Section: Discussionsupporting
confidence: 87%
See 1 more Smart Citation
“…However, this is unlikely since the correlation between cortical thickness and age, in our patient sample, revealed statistically significant areas bilaterally in premotor and primary sensorimotor and visual cortices, confirming previous findings in normal aging (Salat et al, 2004). The low degree of cortical thinning per either TWMLL or disability score in primary sensorimotor areas in our relatively mildly impaired patients suggests that atrophy of primary motor cortex preferentially appears later in the disease course (Sailer et al, 2003).…”
Section: Discussionsupporting
confidence: 87%
“…Total brain atrophy can be viewed as a surrogate marker of the destructive pathological processes taking place in MS and can be observed with magnetic resonance imaging (MRI) by measuring the brain parenchymal fraction, a normalized measure that represents the sum of both gray matter (GM) and WM atrophy (Chard et al, 2002). In addition to establishing global brain atrophy as a pathological feature of the disease, studies have focused separately on the atrophy of cortical GM by measuring decreases in normalized cortical volumes (De Stefano et al, 2003), by means of an ordinal visual scale (Bakshi et al, 2001), or by directly measuring cortical thickness in vivo (Sailer et al, 2003;Chen et al, 2004). MS-related cerebral atrophy appears to be clinically relevant as it correlates with measures of both disability (Bakshi et al, 2001;De Stefano et al, 2003) and disease progression (Hardmeier et al, 2003;Kalkers et al, 2002).…”
Section: Introductionmentioning
confidence: 99%
“…Likewise, some temporal regions (with high regional discriminative weights in our data) have also been found to show a particularly early occurrence of grey matter atrophy and cortical thinning, even after less than 3 years disease duration (Sailer et al, 2003). Recent multivariate predictive modelling results on structural images also report the relative high importance of the superior temporal gyrus and middle temporal gyrus (among others) in distinguishing early from late MS patients (Bendfeldt et al, 2012).…”
Section: Altered Connectivity and Grey Matter Changessupporting
confidence: 74%
“…The thickness of the cortex is of interest as it develops, follows the normal ageing process and changes under a wide variety of neurodegenerative diseases. Recently, imaging studies of cortical thickness have compared the group-wise differences between healthy control subjects and patients with conditions such as sporadic and familial Alzheimer's disease (AD) Gutierrez-Galve et al, 2009;Knight et al, 2009), fronto-temporal lobar degeneration (FTLD) (Du et al, 2007;Rohrer et al, 2009), posterior cortical atrophy , multiple sclerosis (Sailer et al, 2003), Huntington's disease (Rosas et al, 2008), and the changes that occur in healthy controls under normal ageing (Salat et al, 2004).…”
Section: Introductionmentioning
confidence: 99%